Cassava Sciences

SAVAPhase 3

Cassava Sciences is dedicated to advancing innovative therapies for neurodegenerative diseases, with a primary focus on Alzheimer's. Its core technology centers on targeting altered filamin A (FLNA) protein, which the company believes is a key pathological driver of the disease. The company's lead candidate, simufilam, has progressed through Phase 2 and Phase 3 clinical trials, generating significant data and investor attention, though not without controversy. Cassava's strategy is to develop an oral, disease-modifying treatment that could potentially slow or halt the progression of Alzheimer's.

Market Cap

$87.7M

Employees

11-50

Focus

Biotech

SAVA · Stock Price

USD 1.8238.35 (-95.48%)

Historical price data

AI Company Overview

Technology Platform

A drug discovery platform focused on small molecules that restore the normal shape and function of altered filamin A (FLNA) protein, a target hypothesized to be central to Alzheimer's disease pathology.

Pipeline Snapshot

11 drugs in pipeline, 3 in Phase 3

Drug	Indication	Stage
Simufilam + Placebo	Alzheimer Disease	Phase 3
Simufilam	Alzheimer Disease	Phase 3
Simufilam + Placebo	Alzheimer Disease	Phase 3
simufilam	Alzheimer's Disease	Phase 2
Placebo oral tablet + Simufilam 100 mg tablet + Simufilam 50 mg oral tablet	Alzheimer Disease	Phase 2

Funding History

Total raised: $117M

PIPE$100MUndisclosedAug 15, 2021

IPO$15MUndisclosedAug 15, 2000

Seed$2MUndisclosedJun 15, 1998

Opportunities

The primary opportunity is capturing a significant share of the multi-billion dollar Alzheimer's treatment market with an oral, disease-modifying therapy.

Success could also validate the filamin A platform for other neurodegenerative indications.

Risk Factors

Extreme clinical, regulatory, and reputational risk.

The novel mechanism is unproven in Phase 3, and past controversies over data integrity could complicate regulatory review even with positive data.

High cash burn necessitates future dilution.

Competitive Landscape

Competes directly with Biogen/Eisai (Leqembi) and Eli Lilly (donanemab) in the Alzheimer's space. Key differentiation is oral administration and a novel filamin A target, but this also represents a higher scientific risk compared to established amyloid-targeting approaches.